Ningning Zhang
机构：Tianjin Medical University Cancer Institute and Hospital · ORCID：0000-0001-9410-6639
发表论文 28 篇 · 总被引 235 次 · h-index 7
代表论文
- Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancer (2024 · JHEP Reports · 被引 22)
- Fecal microbiota transplantation alleviates cirrhotic portal hypertension in rats via butyrate-mediated HDAC3 inhibition and PI3K/Akt/eNOS signaling regulation (2025 · European Journal of Pharmacology · 被引 13)
- Tumor-intrinsic PRMT5 upregulates FGL1 via methylating TCF12 to inhibit CD8+ T-cell-mediated antitumor immunity in liver cancer (2024 · Acta Pharmaceutica Sinica B · 被引 13)
- Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma (2024 · Cancer Biology and Medicine · 被引 10)
- Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study (2025 · Clinical Cancer Research · 被引 4)
- Liver protection of CACA technical guidelines for holistic integrative management of cancer (2025 · Holistic Integrative Oncology · 被引 3)